XTL Biopharmaceutica Company Insiders

XTL Biopharmaceutica Management Team Effectiveness

The company has return on total asset (ROA) of (0.1378) % which means that it has lost $0.1378 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1307) %, meaning that it created substantial loss on money invested by shareholders. XTL Biopharmaceutica's management efficiency ratios could be used to measure how well XTL Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities. As of December 26, 2024, Return On Tangible Assets is expected to decline to -0.0009. The current year's Return On Capital Employed is expected to grow to -0.33. At present, XTL Biopharmaceutica's Other Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 4.6 M, whereas Total Assets are forecasted to decline to about 2.3 M. The current year's Common Stock Shares Outstanding is expected to grow to about 572.2 M, whereas Net Loss is forecasted to decline to (1.6 M).

XTL Biopharmaceutica Workforce Comparison

XTL Biopharmaceutica Insider Trading

XTL Biopharmaceutica Notable Stakeholders

The success or failure of an entity such as XTL Biopharmaceuticals often depends on how effective the management is. XTL Biopharmaceutica management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of XTL management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the XTL management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of XTL Biopharmaceutica's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, XTL Biopharmaceutica's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of XTL Biopharmaceutica's management manipulating its earnings.

When running XTL Biopharmaceutica's price analysis, check to measure XTL Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XTL Biopharmaceutica is operating at the current time. Most of XTL Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of XTL Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XTL Biopharmaceutica's price. Additionally, you may evaluate how the addition of XTL Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.